Beryl Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 5.09 Cr
as on 24-10-2024
- Company Age 31 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.19 Cr
as on 24-10-2024
- Satisfied Charges ₹ 6.64 Cr
as on 24-10-2024
- Revenue 83.88%
(FY 2023)
- Profit 216.25%
(FY 2023)
- Ebitda 376.65%
(FY 2023)
- Net Worth 10.60%
(FY 2023)
- Total Assets -1.75%
(FY 2023)
About Beryl Drugs
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524606.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 5.09 Cr.
The company currently has active open charges totaling ₹8.19 Cr. The company has closed loans amounting to ₹6.64 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Beryl Drugs Limited India are Neha Sharma as COMPANY SECRETARY and Ashish Baraskar as Cfo. Sudhir Sethi, Sanjay Sethi, Abhinav Naik, and One other member serve as directors at the Company.
- CIN/LLPIN
L02423MP1993PLC007840
- Company No.
007840
- Stock Symbol
BSE : 524606
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Aug 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Beryl Drugs Limited offer?
Beryl Drugs Limited offers a wide range of products and services, including Common Disease Medicines, IV Fluids, Chemical Reagents & Catalysts, Amine Compounds, Injectable Products, Batteries & Charge Storage Devices, Battery Raw Material, Kidney Drugs, Mannitol Injections, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Beryl Drugs?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neha Sharma  | Company Secretary | 01-May-2014 | Current |
| Sanjay Sethi | Managing Director | 12-Dec-2000 | Current |
| Ashish Baraskar | CFO | 04-Sep-2014 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sudhir Sethi | Director | 12-Dec-2000 | Current |
| Abhinav Naik | Director | 30-May-2019 | Current |
| Shreya Saraf | Director | 30-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Beryl Drugs.
Beryl Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 83.88% increase. The company also saw a substantial improvement in profitability, with a 216.25% increase in profit. The company's net worth Soared by an impressive increase of 10.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Beryl Drugs?
In 2023, Beryl Drugs had a promoter holding of 26.38% and a public holding of 73.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jun 2024 | ₹1.75 Cr | Open |
Others Creation Date: 16 May 2024 | ₹4.50 M | Open |
Others Creation Date: 20 Mar 2023 | ₹1.15 Cr | Open |
How Many Employees Work at Beryl Drugs?
Beryl Drugs has a workforce of 22 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Beryl Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Beryl Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
